Bladder Cancer Breakthroughs 2025: New Treatments & Bladder-Sparing Advances

Name: Bladder Cancer Breakthroughs 2025: New Treatments & Bladder-Sparing Advances
Uploaded: 2025-07-10T11:07:17.000Z
Duration: 1 h 50 min 57 s

Bladder Cancer Breakthroughs 2025: New Treatments and Bladder Sparing Advances

Introduction to the Discussion

Stephanie Troll introduces herself as a cancer survivor, patient advocate, and founder of The Patient Story, emphasizing her mission to humanize cancer information.

The Patient Story aims to provide access to top cancer experts like Dr. Shish Kamat from MD Anderson, empowering patients and caregivers with knowledge.

Acknowledgment of Johnson & Johnson as a sponsor for the educational program while maintaining editorial independence; this content is not a substitute for medical advice.

Audience feedback is encouraged through a survey after the discussion, aiming to improve future content.

Focus on Bladder Cancer Treatments

The conversation centers around bladder cancer treatments in 2025 and beyond, following significant meetings such as the American Urological Association annual conference.

Dr. Ashish Kamat joins the discussion; he is an expert in urologic oncology at MD Anderson and leads various patient advocacy efforts.

Importance of Patient Education

Dr. Kamat discusses his motivation for reaching out to patients beyond clinical settings, highlighting that educated patients have better chances of successful treatment outcomes.

He emphasizes that effective treatment requires partnership between healthcare providers and patients, stating that understanding the disease process is crucial for optimal care.

Understanding Bladder Cancer Staging

Dr. Kamat explains how he categorizes bladder cancer patients based on disease state—muscle invasive versus non-invasive—and its implications for treatment options.

He uses an analogy comparing the bladder to a balloon to illustrate how tumors develop from the inner surface towards the muscle layer, which influences treatment decisions.

Treatment Options Based on Disease State

The determination of whether surgery or other therapies are needed depends on whether tumors invade muscle tissue; this guides decisions about radical surgery or bladder preservation strategies.

Understanding Bladder Cancer: Insights on Disease Classification and Patient Advocacy

Disease Classification in Bladder Cancer

Low-grade bladder cancer is often manageable, likened to warts; it requires intervention but typically does not threaten life.

High-grade tumors, even if small, pose significant risks and can be life-threatening despite being non-muscle invasive.

Approximately 70-75% of patients present with non-muscle invasive disease, while 20-25% have muscle-invasive disease; only about 5% present with metastatic disease.

Women are more likely to present with advanced stages of bladder cancer due to misinterpretation of symptoms like blood in urine as menstrual issues.

Importance of Patient Advocacy

Patients should advocate for themselves when experiencing concerning symptoms like blood in urine; dismissing these signs can lead to delayed diagnosis.

Empowerment is crucial; patients must question healthcare responses that downplay their concerns and seek clarity on their health status.

Managing Non-Muscle Invasive Bladder Cancer

Non-muscle invasive bladder cancer behaves like a chronic condition requiring ongoing care due to high recurrence rates.

Engaging patients and families early helps set expectations and understand the importance of regular check-ups and treatments.

Treatment Decisions Based on Patient Preferences

Some patients may prefer drastic measures like radical cystectomy for a "one-and-done" treatment approach, though this is not commonly encouraged.

Treatment decisions are influenced by efficacy and quality of life considerations; understanding patient desires is essential for tailored care.

The Role of Biomarkers in Treatment Strategies

Biomarkers are increasingly important in understanding bladder cancer biology, influencing treatment paradigms and development.

Treatment Paradigms for Non-Muscle Invasive Bladder Cancer

Overview of Biomarker Use in Treatment

The best treatment for non-muscle invasive bladder cancer is biomarker agnostic, primarily using intravesical BCG therapy, which has proven effective without needing biomarkers to guide treatment.

Patients often seek extensive biomarker testing out-of-pocket; however, this testing is not beneficial for upfront treatment decisions and serves more as an educational tool.

If initial therapies fail, biomarker analysis becomes relevant to identify targeted therapies like FGFR or RB directed treatments based on the tumor that develops post-treatment.

Treatment Decision-Making Path

Understanding the landscape of treatment options is crucial; low-grade non-muscle invasive bladder cancer is highly treatable with a good prognosis despite potential recurrences.

For low-grade tumors, the standard approach involves tumor removal via transurethral resection followed by a single chemotherapy instillation into the bladder.

Intermediate Risk Management

Recurrence of low-grade tumors leads to categorization as intermediate risk, necessitating further intervention such as intravesical therapy (chemotherapy maintenance or BCG).

Due to global shortages of BCG, it’s reserved for higher-risk patients; thus, intravesical chemotherapy remains the primary option for intermediate-risk patients.

High-Risk Patient Considerations

High-grade tumors are classified as high risk and may require radical treatment if they show signs of progression towards muscle invasion.

Most high-risk patients can still be treated conservatively with therapies aimed at preserving the bladder while monitoring their condition closely.

Immunotherapy Insights

Intravesical immunotherapy with BCG remains the gold standard for over 40 years due to its effectiveness and lower toxicity when administered directly into the bladder compared to systemic administration.

Bladder Cancer Treatment Insights

Efficacy of BCG Treatment

Most patients (90%) can complete the full three-year course of Bacillus Calmette-Guerin (BCG) treatment when used appropriately, leading to significant efficacy in managing high-grade bladder cancer.

With adequate BCG administration, recurrence rates drop to the teens and progression rates are in single digits, allowing 90% of patients to avoid bladder removal.

Despite its effectiveness, BCG is not foolproof; alternative treatments are necessary for those who cannot tolerate it or if it fails.

Emerging Treatments Post-BCG

New therapies include gene therapy with nataperene, CG oncology drugs, intravesical devices, and Antiva's bio shield for cases where BCG is ineffective.

The discussion emphasizes the importance of understanding these new options for personalized patient care.

Role of Biomarkers in Bladder Cancer

While biomarkers have not been widely utilized in standard bladder cancer treatment yet, there is ongoing research into their potential roles.

In muscle-invasive disease, biomarkers show promise but are still not integrated into clinical practice; they primarily inform prognosis rather than treatment decisions.

Treatment Strategies for Muscle-Invasive Disease

For muscle-invasive bladder cancer, radical cystectomy remains a common recommendation to enhance long-term cure chances; trimodal therapy may be an option for select patients.

Neoadjuvant therapy typically involves cisplatin-based chemotherapy but poses challenges due to toxicity and patient eligibility issues.

Innovations in Combination Therapies

Recent developments suggest combining chemotherapy with immune checkpoint inhibitors prior to surgery could improve long-term outcomes for muscle-invasive patients.

Research on biomarkers aims to identify which patients might respond well enough to systemic therapy that they could avoid cystectomy altogether.

Circulating Tumor DNA as a Prognostic Tool

Elevated levels of circulating tumor DNA (ctDNA) correlate with poorer prognoses; conversely, undetectable ctDNA suggests better outcomes.

Ongoing studies explore whether ctDNA levels can guide treatment escalation or de-escalation strategies while minimizing toxicity without sacrificing efficacy.

Multidisciplinary Approach in Bladder Cancer Care

A multidisciplinary team approach is essential for optimal bladder cancer management; collaboration among specialists enhances patient care quality.

Understanding Bladder Cancer Treatment Options

Holistic Approach to Patient Care

Bladder cancer treatment requires a holistic view of the patient, as it is not solely a surgical, medical, or radiation disease.

Patients should ensure their care team includes various specialists—surgeons, medical oncologists, radiation oncologists, nursing staff—to provide comprehensive support.

Importance of Team Effort in Treatment

A collaborative approach among healthcare professionals is crucial since bladder cancer does not allow for second chances; initial treatment must be optimal.

Patients often feel pressured by non-specialists to make immediate decisions about their treatment options without understanding they have choices.

The Role of Second Opinions

Every patient has the right to seek a second opinion; this can help clarify whether the proposed treatment is indeed the best option for them.

Generalist physicians may not be up-to-date with the latest treatments in bladder cancer due to their focus on multiple cancers.

Specialized Surgical and Chemotherapy Considerations

While chemotherapy can often be administered locally under guidance from specialized protocols, surgery for bladder cancer requires highly trained surgeons with dedicated teams.

It’s essential that patients choose surgeons who perform these procedures regularly and have robust support systems in place.

Radiation Therapy Insights

The expertise of the radiation therapy team—including technologists and oncologists—is critical; it's not just about having advanced machines but also skilled personnel planning treatments.

Finding Reliable Resources for Treatment Decisions

Patients are encouraged to utilize reliable online resources like the Bladder Cancer Advocacy Network (Beacon), which provides patient-focused information.

Consulting local physicians can help identify trusted specialists who may not be listed on major resource sites but offer excellent care.

Community Knowledge and Trust in Physicians

Local community physicians often know which specialists are effective based on personal experiences rather than just academic credentials.

It's important to recognize that many capable practitioners may not have extensive publications but excel at providing quality patient care.

Exploring New Treatments for Bladder Cancer

Recent Developments in Bladder Cancer Treatment

The discussion begins with an acknowledgment of the recent surge in auction developments related to bladder cancer treatments, including gene therapy and new devices.

Focus shifts to high-risk bladder cancer patients who have not responded to BCG treatment, highlighting the dilemma they face regarding subsequent treatment options.

Historically, the standard approach for non-responsive patients was bladder removal due to a lack of effective drugs, which had low success rates (4-5% at two years).

Collaboration between organizations and the FDA has led to a significant increase in drug studies targeting BCG unresponsive disease, marking a pivotal moment in treatment options.

Approved Treatments and Their Mechanisms

The first notable approved drug is premolizumab, a systemic immunotherapy that showed promising results but also presented toxicity concerns; thus, its use as a single agent is limited.

Naperagene, an intravesical gene therapy, allows bladder cells to produce interferon alpha 2b. Administered once every three months, it offers about a 25% chance of disease remission after one year.

Another innovative treatment is the IL15 super agonist, which enhances the immune response when combined with BCG. It boasts over 50% patient response rate at one year but requires concurrent BCG administration.

Emerging Therapies Under Investigation

Several investigational therapies are being explored: creatigene focuses on the RB pathway using a non-oncogenic virus and shows excellent preliminary results despite not yet being approved.

The intravesical pretzel device delivers chemotherapy (gemcitabine) through a silicone device resembling a pretzel. This method allows for sustained drug release without frequent clinic visits.

Nonviral gene therapies like N-gene are also under consideration, providing alternatives for patients hesitant about viral-based treatments or those in smaller hospitals lacking certification for such therapies.

Conclusion on Future Directions

The speaker emphasizes that while there are numerous exciting developments in bladder cancer treatments currently underway, time constraints limit further elaboration on additional therapies like laser treatments.

Exploring Advances in Cancer Therapy

Overview of Current and Future Therapies

The discussion highlights the promising developments in cancer therapies, particularly focusing on bladder cancer, with an emphasis on gene therapy options.

Questions arise regarding the timing and selection of therapies for patients, emphasizing the need for strategic decision-making in treatment approaches across various cancers.

Gene Therapy Insights

The first gene therapy mentioned is naper gene therapy, which is already FDA-approved and currently available to patients.

Another gene therapy from CG Oncology is expected to seek FDA approval within 12 months; however, it remains unavailable for patient use at this time.

Clinical Trials and Patient Considerations

The complexity of recommending treatments arises as not all therapies are suitable for every patient; personalized decisions based on individual circumstances are crucial.

A think tank led by the speaker involved 100 experts discussing optimal drug sequencing for patients, underscoring that no single drug fits all cases.

Treatment Preferences Among Patients

Different treatment regimens may appeal to different patients based on their preferences regarding frequency and side effects; some may prefer less frequent treatments like naper gene therapy.

Other options include combination therapies or devices that release chemotherapy directly into the bladder, showcasing a range of choices tailored to patient lifestyles.

Personalized Medicine Approach

Emphasis is placed on understanding what each patient prioritizes in their life when considering treatment options—highlighting a shift towards personalized medicine.

Clinical Trial Names and Research Updates

The clinical trial names discussed include "Bond Study" for CG Oncology's trial and "Tar 200" & "Tar 210" under J&J’s Moonrise and Sunrise paradigms.

There is uncertainty about final naming conventions once these therapies receive approval, indicating ongoing developments in branding within the pharmaceutical industry.

Overview of Non-Invasive and Muscle Invasive Bladder Cancer Treatments

Insights on Metastatic Disease Treatment

The discussion highlights advancements in non-invasive treatments, particularly focusing on muscle invasive and metastatic diseases. The introduction of EV (enfortumab vedotin) combined with pembrolizumab has significantly altered treatment approaches.

Previously, patients with metastatic disease faced a median survival of 14 months; however, the introduction of EV-pembro has increased this to 30 months, marking a substantial improvement in patient outcomes.

Ongoing research is exploring various second-line and third-line therapies for metastatic disease, including FGFR-directed therapies and antibody-drug conjugates, indicating that further advancements are still needed.

Muscle Invasive Bladder Cancer Strategies

In the context of muscle invasive bladder cancer, efforts are being made to avoid radical cystectomy by utilizing new agent therapies aimed at achieving complete tumor eradication within the bladder.

Traditional methods often led to tumor recurrence if the bladder was not removed; however, emerging data suggests that improved diagnostic tools may allow some patients to receive systemic therapy without surgery.

Clinical Trials and New Protocols

The Modern Study trial aims to assess whether certain patients can safely continue treatment without undergoing bladder removal after achieving specific clinical endpoints.

The Niagara protocol combines gemcitabine and cisplatin with durvalumab (an immune-oncology agent), showing promising results in improving overall survival rates post-radical cystectomy—marking a significant breakthrough compared to previous neo-adjuvant therapies.

Patient Considerations and Quality of Life

This combination therapy represents the first randomized phase three study demonstrating improved overall survival for patients undergoing radical cystectomy after receiving neoadjuvant therapy.

Patients facing muscle invasive disease should actively inquire about alternative treatment options beyond standard care as numerous innovative strategies are currently available or under development.

Side Effects and Quality of Life Impact

Discussions around side effects reveal that while localized symptoms may occur with treatments like gene therapy, they tend to be manageable. There is no significant difference in side effect profiles between different therapeutic approaches currently being studied.

Questions regarding novel devices such as the pretzel device indicate a need for clearer communication about their functionality and impact on patient experience during treatment.

Understanding the Tar 200 Device and Its Clinical Application

Overview of the Tar 200 Device

The Tar 200 device, colloquially known as the "petzel," is inserted into the bladder using a catheter-like method, requiring only local anesthesia.

Patients may initially feel discomfort from having a foreign body in their bladder but often adapt over time, sometimes forgetting its presence.

Treatment Schedule and Patient Experience

In early treatment stages, the device needs to be changed every three weeks; during maintenance, it can remain for up to three months before needing replacement.

Most patients tolerate the device well enough that they might forget about it; however, reminders are necessary to ensure regular follow-ups.

Personalized Treatment Approaches

Discussions with patients regarding their treatment frequency reveal varying preferences; some prefer more frequent visits while others opt for longer intervals between changes.

Emerging agents in clinical trials show promising efficacy numbers compared to existing treatments, though definitive data is still awaited.

The Impact of EV Pembro on Bladder Cancer Treatment

Shift in First-Line Therapy

Traditional first-line chemotherapy for bladder cancer has been primarily platinum-based; many older patients cannot tolerate cisplatin due to comorbidities.

New immuno-oncology therapies and antibody-drug conjugates like enfortumab vedotin have shown improved survival rates compared to standard chemotherapy.

Accessibility Issues

Despite its effectiveness, EV Pembro is not universally available and can be prohibitively expensive for many patients worldwide.

Resource allocation remains a significant challenge in ensuring equitable access to this treatment option across different regions.

Demystifying Clinical Trials for Patients

Understanding Clinical Trials

It's crucial for patients to understand that participating in clinical trials does not equate to being treated as "guinea pigs"; most have other options available.

Benefits of Participation

For eligible patients facing limited options, clinical trials can represent a critical opportunity for potentially life-saving treatments.

Patients involved in clinical trials receive close monitoring and care from dedicated staff, ensuring high-quality oversight throughout their treatment journey.

Clinical Trials: Understanding Patient Commitment

The Importance of Clinical Trials

Participation in clinical trials offers patients the highest standard of care available for their specific disease, while also contributing to broader medical knowledge and future patient care.

Patients are informed that joining a clinical trial is a significant commitment; skipping appointments or parts of the process is not permissible. Financial or social burdens should be communicated upfront.

The speaker emphasizes that if a patient declines participation in a clinical trial, it is not taken personally. The focus remains on what is best for the patient's health and treatment options.

Appreciation and Support

Gratitude is expressed towards Dr. Kamat for his contributions to patient care, highlighting the importance of healthcare professionals in supporting patients through their journeys.

A reminder is given that this discussion does not replace professional medical advice. Participants are encouraged to share feedback through an upcoming survey to improve future educational programs.